It is currently Thu Dec 08, 2016 1:55 am

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Anemone toxin inhibits KV1.3

The Alliance for Children's Therapeutics in collaboration with Dr. Anne Stevens of Seattle Children's Hospital and Kineta Biotech are developing a synthetic protein known as Shk-186. Based on a toxin from the Sun Anemone, Shk-186 inhibits the potassium channel KV1.3 in effector memory T cells and blocks the proinflammatory cytokine cascade leading to autoimmunity. ... evens-lab/ ...
Read more : Anemone toxin inhibits KV1.3 | Views : 879 | Replies : 0

Synthetic protein targets EBV

UW researchers at the Institute of Protein Design have developed a synthetic protein called BINDI which binds to the Epstein-Barr Virus (EBV) protein BHRF1 responsible for immortalizing cells. Inhibition of BHRF1, a BCL2 homologue, may prove to be a useful treatment for EBV related cancers and other conditions stemming from EBV. ... cer-cells/ ... %2900613-8
Read more : Synthetic protein targets EBV | Views : 1280 | Replies : 0

Drug effectiveness in doubt.

On March 21, 2013 it was announced that Professor George C. Ebers, MD, of University of Oxford in London, had been chosen to receive the National MS Society/American Academy of Neurology’s 2013 John Dystel Prize for Multiple Sclerosis. The following quotes come from site.

"His studies of twins have shown that susceptibility is partly genetic and partly environmental, indicating that MS is a complex genetic disease. These ...
Read more : Drug effectiveness in doubt. | Views : 940 | Replies : 0

Positive data from multiple dose phase1 trial of CTP-354

Concert Pharmaceuticals Inc. announced Phase 1 data of CTP-354, a novel, potentially first-in-class, non-sedating, once-daily oral treatment for spasticity. In this multiple ascending dose trial, no sedation or ataxia was observed with CTP-354 and the drug was generally well tolerated across all dose cohorts.

Concert expects to initiate a Phase 2 clinical trial evaluating CTP-354 in patients with spasticity associated with spinal cord injury by the end of 2014..... Read More -
Read more : Positive data from multiple dose phase1 trial of CTP-354 | Views : 996 | Replies : 0

Tecfidera versus aubagio

In brief, I was diagnosed with ms more than 20 years ago. Based on the treatments available then, I chose to wait as the disease was mostly a symptomatic. Now in my late 40's it has come back with a vengeance. MRI shows multiple lesions and I'm having multiple episodes especially with weakness in my left leg. My neurologist wants me to start medication now and my options are tecfidera or aubagio. I'm leaning towards ...
Read more : Tecfidera versus aubagio | Views : 2014 | Replies : 1

Dear friends MEDICINOV Inc. recently announced that it had 50% enrolment for the PHASE 2b clinical trail of MN-166(ibdilast) in progressive M.S patients and the trail is on track please read the rest attached
Read more : RE MEDICINOVA PROVIDES UPDATE ON PHASE 2b TRAILS PMS | Views : 867 | Replies : 0


FRIENDS This was on last friday radio national please listen ... 9_0636.mp3
Read more : NEW CHEMICAL FOUND TO BE DUAL ABILITIES | Views : 994 | Replies : 1

Researchers investigating new treatment for MS

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology® Neuroimmunology & Neuroinflammation.

The phase I studies were the first to test the drug candidate in humans. Studies with animals showed that the drug, which is called anti-LINGO-1, or BIIB033, may be able to reverse the demyelination of the nerves. Anti-LINGO-1 blocks LINGO-1, a central nervous system ...
Read more : Researchers investigating new treatment for MS | Views : 918 | Replies : 0

Phase I trial of ALKS 8700 to treat multiple sclerosis begin

Phase I trial of ALKS 8700 to treat multiple sclerosis begins

Ireland-based biopharmaceutical firm Alkermes has started a Phase I clinical trial of ALKS 8700, a novel monomethyl fumarate (MMF) molecule being developed for the treatment of multiple sclerosis (MS).

The trial will assess the safety, tolerability and pharmacokinetics of several oral formulations of ALKS 8700 compared to both placebo and active control groups in approximately 125 healthy volunteers......... Read More -
Read more : Phase I trial of ALKS 8700 to treat multiple sclerosis begin | Views : 1107 | Replies : 0

Over-the-counter antihistamine, Tavist, being tested

Is anyone taking this over the counter antihistamine and seeing any improvement in their symptoms?
Read more : Over-the-counter antihistamine, Tavist, being tested | Views : 2150 | Replies : 4


Login  •  Register


Total posts 235157 • Total topics 25377 • Total members 16585

Contact us | Terms of Service